Pēdējā atjaunošana :
22/08/2024
Infostab
Saraksti
Kopsavilkums
Meklēt saderības
Y-savienojuma saderības tabula
Literatūras saraksts
pētniecības grupas
valistab
plakāts
Savienojumi
sponsori
Autori
Lietošanas instrukcija
Newsletter
Vincristine sulfate
Ķīmiskā uzbūve
Oriģinālais nosaukums
Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām
Cellecristin
Vācija
Citomid
Čīle, Kolumbija, Meksika, Peru
Crisovin
Ekvadora, Kolumbija, Meksika
Cytocristin
Malaizija
DBL vincristine sulfate
Jaunzēlande, Malaizija
Farmistin
Vācija
Marqibo
Amerikas Savienotās Valstis
Nefixol
Meksika
Oncocristin
Kolumbija
Oncovin
Apvienotie Arābu Emirāti, Austrija, Dānija, Francija, Kolumbija, Lielbritānija, Luksemburga, Maroka, Meksika, Saūda Arābija, Somija, Šveice, Zviedrija
Onkocristin
Vācija
Sindovin
Irāna
Sulfato de vincristine
Venecuēla
Unicristin
Peru
Vinblax
Meksika
Vincasar
Amerikas Savienotās Valstis, Meksika
Vincrisin
Beļģija
Vincristin
Austrija, Šveice, Ungārija, Vācija
Vincristina
Argentīna, Čīle, Ekvadora, Irāna, Islande, Itālija, Kolumbija, Peru, Spānija, Venecuēla
Vincristine
Francija, Grieķija, Luksemburga, Malaizija, Maroka, Norvēģija, Šveice, Tunisija, Turcija, Zviedrija
Vincristine sulfat
Turcija
Vincristine sulfate
Amerikas Savienotās Valstis, Kanāda
Vincristine sulphate
Apvienotie Arābu Emirāti, Ēģipte, Īrija, Jaunzēlande, Lielbritānija, Malaizija, Polija
Vincristinesulfaat
Holande
Vincristinum
Luksemburga
Vincrisul
Spānija
Vinlon Lyo
Peru
Vinracine
Ēģipte, Malaizija
Vintec
Meksika
Literatūras saraksts : Vincristine sulfate
tips
publicēšana
3
Žurnāls
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26
Žurnāls
Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL.
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Am J Health-Syst Pharm 1997 ; 54: 915-920.
32
Žurnāls
Nyhammar EK, Johansson SG, Seiving BE.
Stability of doxorubicin and vincristine sulfate in two portable infusion-pump reservoirs.
Am J Health-Syst Pharm 1996 ; 53: 1171-1173.
57
Žurnāls
Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81
Žurnāls
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84
Žurnāls
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99
Žurnāls
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
144
Žurnāls
Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML.
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags.
Int J Pharm 1991 ; 77: 279-285.
150
Žurnāls
Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
167
Žurnāls
Francomb MM, Ford JL, Lee MG.
Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters.
Int J Pharm 1994 ; 103: 87-92.
169
Žurnāls
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
244
Žurnāls
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248
Žurnāls
Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249
Žurnāls
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251
Žurnāls
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307
Žurnāls
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334
Žurnāls
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335
Žurnāls
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
408
Žurnāls
Beijnen JH, Neef C, Meuwissen OJAT, Rutten JJMH, Rosing H, Underberg WJM.
Stability of intravenous admixtures of doxorubicin and vincristine.
Am J Hosp Pharm 1986 ; 43: 3022-3027.
431
Žurnāls
McRae MP, King JC.
Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures.
Am J Hosp Pharm 1975 ; 33: 1010-1013.
481
Žurnāls
Beijnen JH, Vendrig DEMM, Underberg WJM.
Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids.
J Parenter Sci Technol 1989 ; 43: 84-87.
491
Žurnāls
Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
492
Žurnāls
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
703
Žurnāls
Butler LD, Munson JM, DeLuca PP.
Effect of inline filtration on the potency of low-dose drugs.
Am J Hosp Pharm 1980 ; 37: 935-941.
763
Žurnāls
Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cancer Treat Rep 1985 ; 69: 1325-1326.
857
Žurnāls
Kanke M, Eubanks JL, DeLuca PP.
Binding of selected drugs to a “treated” inline filter.
Am J Hosp Pharm 1983 ; 40: 1323-1328.
905
Žurnāls
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921
Žurnāls
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026
Žurnāls
Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1033
Žurnāls
Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK.
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection.
Am J Health-Syst Pharm 1999 ; 56: 985-989.
1408
Žurnāls
Priston MJ, Sewell GJ.
Stability of three cytotoxic drugs infusions in the Graseby 9000 ambulatory infusion pump.
J Oncol Pharm Practice 1998 ; 4: 143-149.
1410
Žurnāls
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423
Žurnāls
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496
Žurnāls
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1520
Laboratorija
Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1602
Žurnāls
Trissel LA, Zhang Y, Cohen MR.
The stablity of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection.
Hosp Pharm 2001 ; 36: 740-745.
1606
Žurnāls
Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK.
Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection.
Am J Health-Syst Pharm 2001 ; 58: 594-598.
1625
Žurnāls
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662
Žurnāls
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1925
Žurnāls
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953
Žurnāls
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982
Žurnāls
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2094
Žurnāls
Trittler R.
Stability of intravenous admixtures of doxorubicin and vincristine confirmed by LC-MS.
EJHP Science 2006 ; 12, 1: 10-12.
2247
Žurnāls
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3119
plakāts
Henriet Th, El Kateb N, Jourdan N, Faure P, Bellenger P.
Stabilité de la vincristine sans conservateurs.
Congrès HOPIPHARM 2010
3214
Žurnāls
Trittler R, Sewell G.
Stability of vincristine (TEVA) in original vials after re-use in dilute infusions in polyolefin bags and in polypropylene syringes.
EJOP 2011 ; 5,1: 10-14.
3578
Laboratorija
Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3644
Laboratorija
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
4102
Žurnāls
Svirskis D, Behera S, Naidoo N, Beachman J, Raina T, Zhou Y, Berkahn L, Costello I, Gu Y.
Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastromeric pump supporting transition of the EPOCH regimen to oupatient care.
J Oncol Pharm Practice 2018 ;25,4:831-840.
Mentions Légales